BUY
TP: Rs 14,077 | ▲ 32%

ULTRATECH CEMENT | Cement | 21 October 2026

Better placed to handle the challenges, Maintain BUY

- **Industry beating performance at ~14% volume growth lifting capacity utilization at 71% on a higher base, North & South deliver ~20% growth**
- **Price gains limited to ~7% much below cost inflation, drags EBITDA margin to 14.9% (-56bps YoY); EBITDA/tn at Rs916 (+5% YoY)**
- **Revise down FY27E/FY28E/FY29E EBITDA by 9%/7%/6%, 3-year EBITDA CAGR ~17%. Value at 18x EV/EBITDA, revise TP to Rs 14,077. BUY**

Milind Raginwar
Research Analyst
Ayush Dugar
Research Associate
research@bobcaps.in

Pricing gathers pace; volume aids growth: Q2FY27 revenue growth was strong at ~24% YoY to Rs221bn aided by ~14% domestic grey cement volume growth to 36.1mnt. Capacity utilisation improved to 71% vs 66% YoY on a higher capacity base. Grey cement realisations rose ~7% YoY to Rs5,132/t, although prices were broadly stable QoQ amid softness in August. Price hikes in late September lifted exit prices ~3% above Q1FY27 average. White cement volumes fell by ~7% YoY.

Cost inflation weighs on margins despite operating leverage: Operating cost spiked ~10%/8% YoY/QoQ to Rs5,213/t, led by higher fuel and freight costs. Fuel cost rose to ~Rs2.09/kcal vs Rs1.80/kcal YoY and estimated to jump at Rs2.2/kcal. Similarly, freight cost inflated ~6% YoY to ~Rs1,313/t amid diesel price hikes. UTCEM highlighted that fixed cost/tn softened 6% YoY despite capacity additions, cushioning the impact of input-cost inflation.

Profitability moderates QoQ; pricing key to recovery: EBITDA grew ~19% YoY but declined ~28% QoQ to ~Rs33bn, with EBITDA/tn at ~Rs916 (5% YoY) and margin at 14.9% (-56bps YoY). Higher fuel costs and seasonal demand softness checked price hikes collectively weighed on Q2 show. UTCEM expects recent price hikes to offset cost pressures, with full benefit likely to accrue in Q3FY27.

Capex plan beyond 240mtpa under discussion: In Q2FY27 UTCEM added 4.6mtpa with a target of 240+ mtpa by FY28-end. FY27 capex guidance of Rs100bn stays. Details of next expansion phase beyond 240mnt will be released by Q3FY27.

Revise earnings, Maintain BUY: We revise down our FY27E/FY28E/FY29E EBITDA by 9%/7%/6% to recalibrate demand supply dynamics and the cost inflation due to middle-east tension. Despite healthy H1 we feel the pressure on demand will be visible in H2 owing to the changed seasonal factor with drought in many parts of the country. Our FY26-FY29E CAGR is baked at 14%/17%/15% for Revenue/EBITDA/PAT. Given the healthy cost measures, strong growth and a steady balance sheet, we continue to assign UTCEM 18x EV/EBITDA multiple (rolling over to September 2028) to arrive at TP of Rs14,077 (from Rs 14,679) and maintain BUY.

Key changes

Target	Rating
▼	◄ ►

Ticker/Price	UTCEM IN/Rs 10,650
Market cap	US$ 32.4bn
Free float	40%
3M ADV	US$ 33.9mn
52wk high/low	Rs 13,110/Rs 10,325
Promoter/FPI/DII	60%/15%/17%


Source: NSE | Price as of 19 Oct 2026

Key financials

Y/E 31 Mar	FY26P	FY27E	FY28E
Total revenue (Rs mn)	8,21,697	9,71,655	10,76,574
EBITDA (Rs mn)	1,54,796	1,83,196	2,22,503
Adj. net profit (Rs mn)	75,090	76,118	94,626
Adj. EPS (Rs)	254.8	258.3	321.1
Adj. ROAE (%)	10.4	10.3	12.4
Adj. P/E (x)	41.8	41.2	33.2
EV/EBITDA (x)	20.9	17.6	14.3
Adj. EPS growth (%)	17.1	1.4	24.3

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE

Fig 1 – Earnings call highlights

Parameter	Q2FY27	Q1FY27	Our view
Volumes and realisations	Domestic grey cement sales volumes grew 13.8% YoY to ~36.1mt, outperforming estimated industry growth of ~10%. Capacity utilisation improved to 71% vs 66% YoY despite a higher capacity base. Growth was broad-based, with North growing >20%, South 15–20%, West and Central ~10% each, while East grew ~5% amid heavy rainfall. Management indicated that demand remained resilient, supported by individual home builders, urban housing and infrastructure. Pan-India average cement prices were broadly stable QoQ, with the quarterly average down ~1-1.5% due to weak August pricing. However, prices strengthened in September, with trade prices rising Rs7–10/bag MoM exiting September ~3% above Q1 average. October price have been rising higher and holding ground. Management expects the benefit of price hike should percolate in Q3. Premium cement contributed ~37% of sales, while blended cement accounted for 67.3%.	Consolidated sales volumes crossed ~41.3mt, domestic grey cement volumes grew ~13.1% YoY, outperforming industry growth of ~7-8%. Capacity utilisation improved to 81% vs ~79% YoY on an expanded 200.1mtpa base. Management highlighted that UltraTech brand grew ~21% YoY, aided by complete migration of India Cements and Kesoram brands to UltraTech ahead of schedule. Trade volumes and premium products continued to witness healthy traction, supporting blended realisations. Cement prices improved in Q1 with June exit prices higher across most regions, led by East and South, West and Central were steady and North performed well. UTCEM expects prices to remain stable in Q2 and strengthen further with the busy season. White cement demand remained healthy with premiumisation supporting growth.	UTCEM has maintained higher capacity utilisation, despite demand weakness only indicating that utilisation rates will stay ahead of the industry. However, monsoon adversity may impact rural demand that will keep pricing in check. With cost levers fully explored to off-set inflationary fuel inflation cement pricing will remain the key to offset cost inflation Respite is in exit prices staying higher than average Q2 prices.
Margins	Fuel cost contribution rose sharply (West Asia impact) from ~Rs45/bag to ~Rs51/bag; kcal rate reached Rs2.09 and is expected ~Rs2.2 in H2. Petcoke share reduced to ~25%, petcoke rates have reached to USD 170-180/t. Management highlighted that fixed cost/t were ~6% lower YoY despite new capacity additions, as absolute fixed costs rose only ~4% against volume growth of 13.8%. Net profit rose 21% YoY. India Cements delivered ~Rs500/t improvement in performance as major kiln upgrades and efficiency capex are planned to drive it towards healthier EBITDA/tn by FY28. Management intends to keep EBITDA/tn higher YoY in the next two quarters through price increases absorbing cost inflation.	Consolidated EBITDA came at Rs51.5bn, while operating EBITDA/t improved to Rs1,214/t. India Cements reported EBITDA/t of Rs603 (vs Rs497 in Q4FY26. India Cement revenue grew by 21% YoY to Rs 9.9bn (like-to-like basis). Imported fuel costs inflated sharply in Q1FY27 leading to Rs 25-40/t negative impact. UTCEM indicated a Rs130–140/t impact from fuel inflation. Packing bag costs also spiked from Rs 9/bag to Rs 12/bag. Additionally cost of limestone raising increased by 13-14% due to the increase in diesel cost. However, these headwinds were partly offset through higher renewable power usage 45.6% YoY with Q1FY27 ending rate of ~47%, prudent fuel mix optimisation, operating leverage and logistics efficiencies.	Thrust on cost savings on track with contributions by better clinker conversion ratio, prudent churn in fuel mix, logistics cost savings and higher usage of green energy. We expect UTCEM cost saving guidance may be marginally postponed given ICEM and KSI asset acquisition and the current cost pressures due to geo-political pressure. Levers gradually incrementally shift towards pricing strength over cost savings.
Capacity	UTCEM commissioned 4.6mtpa of additional capacity during Q2, including 3.6mtpa at Petnikota, Andhra Pradesh, and 1mtpa through debottlenecking at existing units. Domestic grey cement capacity increased to 204.7mtpa, taking global capacity to 210.1mtpa. Management reiterated that the company remains on track to reach >240mtpa capacity by March 2028. Capacity utilisation was above 70% in North and South, close to 70% in West, and around 60% in East partly due to prolonged rainfall. Management indicated that next phase of organic expansion, with detailed plans will be announced before FY27-end.	Domestic grey cement capacity currently is 200.1mtpa (global capacity 205.5mtpa). Projects under execution are backed by ~Rs170bn and will increase total capacity beyond 242mtpa, including 212.7mtpa domestic grey cement capacity by FY27-end. Management reiterated that capacity expansion remains on schedule with no equipment or execution bottlenecks. Renewable power capacity increased to ~1.9GW after commissioning 71MW renewable and 19MW WHRS during the quarter. Management aims to reach 2.5-3GW of capacity by Q2YF27.	Capacity expansion plans are on schedule. Both organic and inorganic growth would imply UTCEM's drive towards 240mn by FY28. This only ensures that UTCEM will continue to grow at industry beat pace by a margin. Defining capacity additions beyond 240mt in the next phase plans only reiterates management confidence in improved demand in the medium term as the current challenges fade.

Parameter	Q2FY27	Q1FY27	Our view
Capex	Management maintained its FY27 capex guidance at ~Rs100bn, with H1FY27 capex at ~Rs58.8bn with precise guidance to be given in Q3. Net debt/EBITDA increased to ~1.26x at September-end from 0.94x at March-end, reflecting capex, dividend payments and other funding requirements. Management expects the ratio to fall below 1x by March 2027. Of the planned Rs18bn investment in UltraVolt, ~Rs11bn had been spent or committed, with the balance expected to be deployed over the next two quarters. No additional investment beyond the sanctioned amount has been approved.	Management reiterated its disciplined capital allocation strategy with growth capex funded through internal accruals while maintaining Net Debt/EBITDA at 0.87x (vs 0.94x in Q4FY26), well below its <1x target. Efficiency improvement capex deployed for India Cements continues to be ~Rs20bn planned for cost reduction initiatives, renewable energy and operational upgrades. The Wires & Cables project remains on schedule with commercial production expected during Q3FY27, while management ruled out any major incremental diversification beyond existing building material businesses.	Healthy cashflows and sharp focus on maintaining balance sheet health have been sustained despite aggressive capital expenditure plans. Additionally, transition of the acquired assets will be a key task in FY27. This is in addition to the current cost pressures emanating from external pressure. We keep a close watch on UTCEM's investment in Star Cement and the capital allocation in the Wires and cables business.
Other key points	Management expects industry demand to remain strong through H2FY27, maintaining its outlook for industry growth of ~7–8% and double-digit growth for UTCEM. Management expects rural demand to soften in some pockets but sees support from urban housing, infrastructure and private-sector capex. Green power contributed ~48% of power requirements, following the addition of 117MW renewable capacity and 10MW of waste heat recovery during the quarter. AFR systems were commissioned at two plants, taking the thermal substitution rate to ~7.2%. UltraVolt was launched on 3 September; production of house wires, panel wires and multi-core cables have begun, while the remaining power and control cable lines are expected to be commissioned in H2. More than 1,500 UltraTech Building Solutions channel partners have signed up, with retail reach exceeding 80,000 touchpoints reaching 15,000+ pin codes.	Management reiterated confidence in double-digit volume growth in FY27, supported by strong housing, infrastructure and commercial construction demand. East India is witnessing an improving demand cycle, while Maharashtra infrastructure investments and urban construction remain major growth drivers. India Cements' turnaround continues ahead of plan, with premium product mix improving and clinker conversion ratio steadily rising.	The entry in new business of wires and cables is a step towards completion of the building material chain under one stop. In the early phase investment of Rs11bn is a right step though capital allocation and returns will be watched keenly. The entry in the new business is fresh but the moves are in the right direction. We will keenly watch the investments and returns of the new business. For Cement demand continuity will be the key and could be under stress with macro-economic weakness owing to geo-political issues and importantly sub-par monsoon. Further, newly added capacity will imply focus on growth while maintaining difficult tasks of retaining margins when cost curve is inflated.

Source: Company, BOBCAPS Research | CCI: Competition Commission of India

Fig 2 – Key quarterly metrics

	Q2FY27	Q2FY26	YoY (%)	Q1FY27	QoQ (%)	Q2FY27E	Deviation (%)
Volumes (mn mt)	36.1	31.8	13.6	39.3	(8.3)	38.1	(5.3)
Cement realisations (Rs/t)	5,132	4,806	6.8	5,075	1.1	5,062	1.4
Operating costs (Rs/t)*	5,213	4,754	9.7	4,821	8.1	4,917	6.0
EBITDA/t (Rs)	916	872	5.0	1,165	(21.3)	898	2.1


Source: Company, BOBCAPS Research | *Aggregate cost

Fig 3 – Quarterly performance

(Rs mn)	Q2FY27	Q2FY26	YoY (%)	Q1FY27	QoQ (%)	Q2FY27E	Deviation (%)
Net Sales	**2,21,077**	**1,78,644**	**23.8**	**2,35,355**	**(6.1)**	**2,21,547**	**(0.2)**
Expenditure							
Change in stock	(3,762)	(561)	570.6	(1,162)	223.8	(451)	734.1
Raw material	35,336	27,799	27.1	35,044	0.8	34,252	3.2
purchased products	18,770	8,794	113.4	17,149	9.5	17,031	10.2
Power & fuel	48,319	38,665	25.0	47,619	1.5	47,816	1.1
Freight	47,342	39,264	20.6	51,568	(8.2)	50,940	(7.1)
Employee costs	10,481	9,410	11.4	9,916	5.7	9,510	10.2
Other exp	31,550	27,573	14.4	29,429	7.2	28,252	11.7
Total Operating Expenses	1,88,035	1,50,943	24.6	1,89,563	(0.8)	1,87,349	0.4
EBITDA	**33,042**	**27,701**	**19.3**	**45,792**	**(27.8)**	**34,198**	**(3.4)**
EBITDA margin (%)	**14.9**	**15.5**	**(56bps)**	**19.5**	**(451bps)**	**15.4**	**(49bps)**
Other Income	846	726	16.4	1,212	(30.2)	911	(7.2)
Interest	4,944	3,962	24.8	3,963	24.8	4,123	19.9
Depreciation	10,678	10,018	6.6	10,515	1.6	10,915	(2.2)
PBT	18,265	14,448	26.4	32,526	(43.8)	20,071	(9.0)
Non-recurring items	0	0	0.0	0	0.0	0	
PBT (after non-recurring items)	18,265	14,448	26.4	32,526	(43.8)	20,071	(9.0)
Tax	4,947	3,810	29.8	8,555	(42.2)	4,516	9.5
Reported PAT	13,318	10,638	25.2	23,971	(44.4)	15,555	(14.4)
Adjusted PAT	**13,318**	**10,638**	**25.2**	**23,971**	**(44.4)**	**15,555**	**(14.4)**
NPM (%)	**6.0**	**6.0**	**7bps**	**10.2**	**(416bps)**	**7.0**	**(100bps)**
Adjusted EPS (Rs)	**46.1**	**36.9**	**25.2**	**83.1**	**(44.4)**	**53.9**	**(14)**


Source: Company, BOBCAPS Research

Fig 4 – Efficient capacity absorption and infrastructure and retail demand to drive growth




Source: Company, BOBCAPS Research

Fig 5 – October prices are on rise and are expected to sustain driving realisation




Source: Company, BOBCAPS Research

Fig 6 – Truncated monsoon kept disruption limited but cost pressure continues to mount on




Source: Company, BOBCAPS Research

Fig 7 – Operating cost pressured by fuel cost inflation and capacity additions




Source: Company, BOBCAPS Research

Fig 8 – Lean period discount less pronounced as diesel inflation sustains



Source: Company, BOBCAPS Research

Fig 9 – Green power share creeping up offsetting fuel cost volatility



Source: Company, BOBCAPS Research

Valuation Methodology

We revise our FY27E/FY28E/FY29E EBITDA estimates to recalibrate demand supply dynamics and the importantly the cost inflation due to middle-east tension. Despite healthy H1 we feel the pressure on demand will be visible in H2 owing to the changed seasonal factor with drought in many parts of the country. Our FY26-FY29E CAGR is baked at 14%/17%/15% for Revenue/EBITDA/PAT. UTCEM is focused on saving cost, to prepare it for short/long-term industry challenges and is the correct strategy for chasing prices. Recovery in FY27 will depend on demand continuity and remains key monitorable. With growth plans, intact and will sustain beyond FY29; guard on margins will be driven by focus on cost savings and healthy pricing.

Cost savings measure guidance augurs well for providing a boost to EBITDA/tn on a higher volume base in the next two years, even if prices stay listless. The growth will be even in challenging times ahead of industry. Further, debt on balance sheet is in a manageable trajectory, though initially, the book may be mildly stressed. Diversification in new business vertical is a correct step and will be keenly watched. Capital allocation is lower and in small but steady manner and augurs well. We have not factored any income from this vertical in our estimates.

Given the healthy cost measures, strong growth and a steady balance sheet, we continue to assign UTCEM 18x EV/EBITDA multiple (rolling over to September 2028) to arrive at TP of Rs14,077 (from Rs 14,679) and maintain BUY. The stock trades at a replacement value of $250/tn (Rs28.8bn/mn tonne), which is the deserved premium for a large size pan-India presence efficiently managed company.

Fig 10 – Revised estimates

(Rs mn)	New			Old			Change (%)		
	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E	FY27E	FY28E	FY29E
Revenue	9,71,655	10,76,574	12,00,449	9,64,853	10,69,432	11,92,949	0.7	0.7	0.6
EBITDA	1,83,196	2,22,503	2,60,637	2,01,264	2,39,905	2,77,990	(9.0)	(7.3)	(6.2)
Adj PAT	76,118	94,626	1,13,733	89,489	1,07,330	1,26,401	(14.9)	(11.8)	(10.0)
Adj EPS (Rs)	258.3	321.1	386.0	303.7	364.2	428.9	(14.9)	(11.8)	(10.0)

Source: BOBCAPS Research, Note:

Fig 11 – Key assumptions

Parameter	FY26P	FY27E	FY28E	FY29E
Volumes (mt)	145.56	161.27	175.78	193.36
Growth(%)	20.00	10.8	9.0	10.0
Realisations (Rs/tn)	5,278	5,384	5,505	5,615
Growth(%)	5.84	2.0	2.2	2.0
Operating costs (Rs/tn)	4,587	4,809	4,790	4,799
Growth (%)	(3.82)	4.8	(0.4)	0.2
EBITDA/tn (Rs)	1052	1057	1189	1276
Growth (%)	6.16	0.4	12.5	7.3


Source: Company, BOBCAPS Research

Fig 12 – Valuation summary

Business (Rs mn)	September 2028E
Target EV/EBITDA (x)	18.0
EBITDA	2,41,570
Target EV	**42,29,890**
Total EV	42,29,890
Net debt	82,041
Target market capitalisation	41,47,848
Target price (Rs/sh)	**14,077**
Weighted average shares (mn)	294.7


Source: Company, BOBCAPS Research Note: Valuations based on 1-year forward earnings (Sept 2028)

Fig 13 – EV/EBITDA band: Valuations moderation healthy sign and regain strength in the medium term




Source: Company, Bloomberg, BOBCAPS Research

Fig 14 – EV/EBITDA 1YF: Forward earnings converging with mean, pointing towards better headroom




Source: Company, Bloomberg, BOBCAPS Research

Fig 15 – EV/tonne: Replacement cost at valuations for industry leader and will stay elevated



Source: Company, Bloomberg, BOBCAPS Research

Fig 16 – EV/tonne 1YF: Valuations are moderating and will reverse back in the medium term



Source: Company, Bloomberg, BOBCAPS Research

Key Risks

Key downside risks to our estimates:

- Increasing competitive intensity and capacity addition may have a negative impact on the cement sector pricing and could be detrimental for the industry and UTCEM.
- Slower than expected demand growth and additional capacities may put further pressure on pricing.
- Continued energy cost spikes due to global uncertainties could dampen profitability.

Financials

Income Statement

Y/E 31 Mar (Rs mn)	FY25A	FY26P	FY27E	FY28E	FY29E
Total revenue	**7,08,573**	**8,21,697**	**9,71,655**	**10,76,574**	**12,00,449**
EBITDA	1,22,961	1,54,796	1,83,196	2,22,503	2,60,637
Depreciation	(37,391)	(40,551)	(46,633)	(55,960)	(67,152)
EBIT	92,504	1,17,606	1,43,212	1,73,346	2,00,338
Net interest inc./(exp.)	(14,653)	(16,300)	(38,390)	(41,736)	(42,553)
Other inc./(exp.)	6,934	3,361	6,649	6,804	6,853
Exceptional items	(881)	(1,038)	0	0	0
EBT	76,970	1,00,268	1,04,822	1,31,611	1,57,786
Income taxes	(15,044)	(26,215)	(28,704)	(36,985)	(44,052)
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
Reported net profit	**61,926**	**74,052**	**76,118**	**94,626**	**1,13,733**
Adjustments	(881)	(1,038)	0	0	0
Adjusted net profit	**62,807**	**75,090**	**76,118**	**94,626**	**1,13,733**

Balance Sheet

Y/E 31 Mar (Rs mn)	FY25A	FY26P	FY27E	FY28E	FY29E
Accounts payables	1,21,662	1,46,637	1,75,482	2,06,692	2,27,234
Other current liabilities	99,027	84,385	1,02,978	1,05,058	1,07,138
Provisions	10,356	10,904	11,494	12,130	12,816
Debt funds	2,08,395	2,04,796	1,86,207	1,91,863	1,93,671
Other liabilities	81,976	85,058	86,508	87,958	89,408
Equity capital	2,947	2,947	2,947	2,947	2,947
Reserves & surplus	6,93,826	7,43,687	7,30,209	7,92,081	8,71,337
Shareholders' fund	6,91,988	7,46,687	7,33,156	7,95,028	8,74,284
Total liab. and equities	**12,13,404**	**12,78,467**	**12,95,825**	**13,98,728**	**15,04,551**
Cash and cash eq.	49,139	52,697	51,327	95,473	1,25,978
Accounts receivables	43,778	48,671	60,215	69,667	80,972
Inventories	85,668	83,873	1,01,842	1,15,788	1,32,400
Other current assets	96,720	88,293	98,300	1,08,130	1,18,943
Investments	1,23,886	1,25,911	1,26,411	1,33,411	1,33,411
Net fixed assets	6,89,193	7,19,062	7,16,726	7,39,942	7,81,218
CWIP	59,560	94,268	75,000	70,000	65,000
Intangible assets	65,460	65,691	66,004	66,317	66,630
Deferred tax assets, net	0	0	0	0	0
Other assets	0	0	0	0	0
Total assets	**12,13,404**	**12,78,467**	**12,95,825**	**13,98,728**	**15,04,551**

Cash Flows

Y/E 31 Mar (Rs mn)	FY25A	FY26P	FY27E	FY28E	FY29E
Cash flow from operations	**97,026**	**1,34,234**	**1,32,371**	**1,52,733**	**1,66,915**
Capital expenditures	(1,81,479)	(1,05,359)	(25,342)	(74,490)	(1,03,741)
Change in investments	(72,652)	(10,564)	(10,500)	(57,000)	(50,000)
Other investing cash flows	0	0	0	0	0
Cash flow from investing	**(2,54,131)**	**(1,15,923)**	**(35,842)**	**(1,31,490)**	**(1,53,741)**
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	1,12,796	(3,600)	(18,589)	5,656	1,808
Interest expenses	10	10	10	10	10
Dividends paid	(14,131)	(83,097)	(30,691)	(32,754)	(34,478)
Other financing cash flows	58,734	63,404	(58,620)	0	0
Cash flow from financing	**1,57,399**	**(23,292)**	**(1,07,899)**	**(27,098)**	**(32,669)**
Chg in cash & cash eq.	**294**	**(4,981)**	**(11,370)**	**(5,854)**	**(19,495)**
Closing cash & cash eq.	**49,139**	**52,697**	**51,327**	**95,473**	**1,25,978**

Per Share

Y/E 31 Mar (Rs)	FY25A	FY26P	FY27E	FY28E	FY29E
Reported EPS	214.5	251.3	258.3	321.1	386.0
Adjusted EPS	217.6	254.8	258.3	321.1	386.0
Dividend per share	69.9	240.0	90.0	95.0	467.0
Book value per share	2,397.0	2,533.5	2,488.0	2,697.9	2,966.9

Valuations Ratios

Y/E 31 Mar (x)	FY25A	FY26P	FY27E	FY28E	FY29E
EV/Sales	4.5	3.9	3.3	3.0	2.6
EV/EBITDA	25.7	20.9	17.6	14.3	12.1
Adjusted P/E	49.0	41.8	41.2	33.2	27.6
P/BV	4.4	4.2	4.3	3.9	3.6

DuPont Analysis

Y/E 31 Mar (%)	FY25A	FY26P	FY27E	FY28E	FY29E
Tax burden (Net profit/PBT)	80.5	73.9	72.6	71.9	72.1
Interest burden (PBT/EBIT)	84.2	86.1	73.2	75.9	78.8
EBIT margin (EBIT/Revenue)	13.1	14.3	14.7	16.1	16.7
Asset turnover (Rev./Avg TA)	65.0	66.0	75.5	79.9	82.7
Leverage (Avg TA/Avg Equity)	1.7	1.7	1.7	1.8	1.7
Adjusted ROAE	9.8	10.4	10.3	12.4	13.6

Ratio Analysis

Y/E 31 Mar	FY25A	FY26P	FY27E	FY28E	FY29E
YoY growth (%)					
Revenue	4.9	16.0	18.2	10.8	11.5
EBITDA	(2.6)	25.9	18.3	21.5	17.1
Adjusted EPS	(10.0)	17.1	1.4	24.3	20.2
Profitability & Return ratios (%)					
EBITDA margin	17.1	18.8	18.6	20.4	21.5
EBIT margin	13.1	14.3	14.7	16.1	16.7
Adjusted profit margin	8.9	9.1	7.8	8.8	9.5
Adjusted ROAE	9.8	10.4	10.3	12.4	13.6
ROCE	10.7	11.7	14.0	16.7	17.9
Working capital days (days)					
Receivables	23	22	23	24	25
Inventory	44	37	38	39	40
Payables	75	80	80	87	87
Ratios (x)					
Gross asset turnover	0.8	0.8	0.9	1.0	1.0
Current ratio	1.2	1.1	1.1	1.2	1.3
Net interest coverage ratio	6.3	7.2	3.7	4.2	4.7
Adjusted debt/equity	0.3	0.3	0.3	0.2	0.2

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**
Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**
SEBI Research Analyst Registration No: **INH000000040 (Perpetual)**
SEBI Stock Broker Registration No: **INZ000159332**
SEBI Depository Participant Registration No: **IN-DP-728-2022**
SEBI Merchant Banker Registration No: **INM000009926**
Phone: +91-22-61389300
Name of the Compliance Officer: Mr. Sameer Khobrekar
Email ID: Compliance@bobcaps.in; Phone no.: +91-22-61389358
For any queries or grievances, you may contact the Grievance Officer.
Name of the Grievance Officer: Mr. Nilesh Mehta
Email ID: head-customercare@bobcaps.in; Phone no: 92288 60945

Brand Name: **BOBCAPS**
Website: **https://www.bobcaps.in/**
CIN: **U65999MH1996GOI098009**

Logo:

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%


HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Ratings and Target Price (3-year history): ULTRATECH CEMENT (UTCEM IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("**MSL**") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as **"MAYBANK**"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.